These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34793662)

  • 1. Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy.
    Kim R; Hong JY; Lee J; Kwon GY; Jeong BC; Park SH
    Cancer Res Treat; 2022 Jul; 54(3):894-906. PubMed ID: 34793662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
    Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
    Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
    Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
    Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
    Nishiyama H; Tsuzuki T; Ohyama C; Matsuyama H; Shinozaki K; Hayashi Y; Hayashi N; Koto R; Shin E; Ogawa O
    Int J Clin Oncol; 2023 Oct; 28(10):1398-1410. PubMed ID: 37498492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment.
    Jin J; Li J; Peng C; Chen J; Xu G; Pan S
    Anticancer Drugs; 2023 Jul; 34(6):797-802. PubMed ID: 36729952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
    Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett J; Xu B; Downes MR
    J Clin Pathol; 2021 Jan; 74(1):53-57. PubMed ID: 32471889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.
    Mao S; Zhang J; Guo Y; Zhang Z; Wu Y; Zhang W; Wang L; Geng J; Yan Y; Yao X
    Drug Des Devel Ther; 2019; 13():291-300. PubMed ID: 30666091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
    Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
    J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
    Ma YT; Hua F; Zhong XM; Xue YJ; Li J; Nie YC; Zhang XD; Ma JW; Lin CH; Zhang HZ; He W; Sha D; Zhao MQ; Yao ZG
    Front Immunol; 2023; 14():1269097. PubMed ID: 38022513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.
    de Jong JJ; Stoop H; Boormans JL; van Leenders GJLH
    Virchows Arch; 2021 Oct; 479(4):705-713. PubMed ID: 33909149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis.
    Zhang J; Song L; Zhu H; Liu Q; Wang D
    Front Immunol; 2022; 13():986911. PubMed ID: 36248912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutoff values of PD-L1 expression in urinary cytology samples for predicting response to immune checkpoint inhibitor therapy in upper urinary tract urothelial carcinoma.
    Chen Y; Fu J; Li Z; Chen Q; Zhang J; Yang Y; Yang P; Wang J; Liu Z; Cao Y; Zhang Y
    Cancer Cytopathol; 2023 Mar; 131(3):179-187. PubMed ID: 36397276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.